Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

For Merck, Outcomes Trials Offer Fast Track To Payers

Feb 01 2012

• By Bridget Silverman

Related Content

Vorapaxar Woes Increase Pressure On Remainder Of Merck CV Pipeline

Jan 24 2011

Back To The Drawing Board For Portola After Merck Returns Betrixaban

Mar 24 2011

Merck Looks Beyond First-In-Class Only As It Seeks To Bolster R&D Productivity

Nov 28 2011

Pharma/Payer Deals: 2011 Saw Important Step In Shift To Value-based R&D

Jan 09 2012

With Its Hypertension Franchise in Crisis, Novartis Restructures

Jan 13 2012

Merck On Track To File Novel Sleep Aid Suvorexant In 2012

Feb 01 2012

The SHARP “Approval”: Merck Gets <em>Vytorin</em> Labeling Change, But Not The CV Outcomes Claim It Sought

Feb 13 2012

Freed From Merck Deal, Portola Set To Move Betrixaban Forward With $89M Funding

Nov 22 2011

Astellas Discontinues Development Of Factor Xa Inhibitor Darexaban

Sep 30 2011

Related Companies

Merck & Co., Inc.

AstraZeneca PLC

Sanofi

Pfizer Inc.

Portola Pharmaceuticals, Inc.

Astellas Pharma, Inc.

Novartis AG

Karo Pharma AB

Eli Lilly and Company

Roche Holding AG

Additional Topics

Clinical Trials BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window